Fifth Third Bancorp (FITB.K): 2Q26 Preview – We See Path to Med-Term Targets, Just Feels Priced in Already

Research evidence excerpt

Fifth Third Bancorp (FITB.K): 2Q26 Preview – We See Path to Med-Term Targets, Just Feels Priced in Already

Action |

22 Jun 2026 16:05:00 ET │ 14 pages

Fifth Third Bancorp (FITB.K)

2Q26 Preview – We See Path to Med-Term Targets, Just Feels Priced In

Already

CITI’S TAKE Neutral

Sentiment heading into 2Q earnings has turned more bullish (Figure 3) Price (18 Jun 26 16:00) US$52.74

following recent conference updates where mgmt indicated 2Q expenses Target price US$53.00

were trending towards the lower end of their prior $1.87-$1.89 bil range,

Expected share price return 0.5% implying upside on PPNR. We leave our expense numbers unchanged as

our prior estimates were already at the low-end, with our full-year Expected dividend yield 3.2%

estimates at the high-end of mgmt’s $7.2-$7.3 bil guide (excl. acquisition Expected total return 3.7%

charges). We see downside into the quarter and 2026 on stronger Market Cap US$47,799M

expenses, though consensus comparison still appears complicated by

CMA acquisition. We see focus centered around balance sheet growth,

particularly FITB’s efforts to grow consumer deposits and the resulting

impact to deposit costs, alongside fees as we get first full-quarter impact Benjamin GerlingerAC

with CMA, which consensus seemed to have reset after 1Q earnings. With +1-212-816-3538

no upside to consensus in ’26 and our estimates in-line with mgmt benjamin.gerlinger@citi.com

guidance, stock already feels priced for above peer returns. Mikhail Mrotchek

+1-212-816-2345

Estimate Changes — 2026E EPS increases 10c to $2.85 (vs. FactSet consensus of misha.mrotchek@citi.com

$3.80), 2027E EPS increases 25c to $5.05 (vs. FactSet consensus of $4.92), and Kaili Wang, CFA

2028E EPS increases 25c to $5.50 (see Figure 1 for more detail on estimate changes).